Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025

Accounts receivables outflow shrinks to CN¥0

Q4 FY2025 accounts receivables was CN¥0, compared with CN¥62.75M a year earlier. Over 3 fiscal years it compounded at +659.2% a year.

Context

  • Accounts receivables amounted to 30.4% of revenue in FY2025, up 24.0 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥0— QoQ
Last fiscal yearDec 2025
-CN¥169.8M-370.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-370.6%——
3-year CAGR+659.2%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

CNY · from the cash flow

Latest · FY2025
(169.8M) CNY
Year-over-year change
-370.6%

Accounts Receivables vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -370.6% is the 5th highest of 6, against a peer median of -7.6%.
  • Accounts receivables amounts to 30.4% of revenue for AAPG, versus a peer median of 5.7%.
AAPG Competitors
Accounts Receivables for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥169.8M CNY-370.6%+659.2%30.4%
ZLABZai Lab LimitedLTM Jun 2026$26.3M USD+212.9%—5.8%
VSTMVerastem, Inc.LTM Mar 2026$10.16M USD-39169.2%—20.5%
NUVBNuvation Bio Inc.LTM Jun 2026$9.62M USD+260.7%—5.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$5.15M USD-7.6%-45.1%14.8%
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 USD———
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 USD——0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD——0.0%
IMRXImmuneering CorporationLTM Mar 2026$0 USD———
Peer median (excluding AAPG) —-7.6%-45.1%5.7%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(832.25M)(887.17M)(932.86M)(395.26M)(1.24B)
Depreciation & Amortization28.33M62.92M93.2M93.17M86.48M
Deferred Income Tax00000
Stock-Based Compensation46.97M22.11M31.5M20.92M20.87M
Change in Working Capital(74.91M)104.41M(9.15M)110.97M(143.5M)
Accounts Receivables(53.97M)(388K)(91.54M)62.75M(169.8M)
Inventory(3.93M)(5.52M)(6.72M)9.57M(26.2M)
Accounts Payables024.7M(23.11M)19.52M14.77M
Other Working Capital(17.01M)85.62M112.22M19.13M37.72M
Other Non-Cash Items227.18M43.82M91.23M58.84M98.07M
Operating Cash Flow(604.68M)(653.92M)(726.08M)(111.36M)(1.17B)
Capital Expenditures(436.63M)(236.96M)(56.84M)(24.29M)(27.57M)
Acquisitions (Net)(36.2M)(20M)(20M)(25.52M)(43.34M)
Purchases of Investments(1.78B)(130M)0(312.23M)(929.14M)
Sales of Investments1.79B0000
Other Investing Activities(879K)(31.32M)88.03M(312.23M)0
Investing Cash Flow(466.52M)(384.61M)21.92M(362.04M)(1B)
Debt Repayment548.59M695.87M(13.36M)(145.34M)307.26M
Common Stock Issued1.3B0470.08M533.94M2.3B
Common Stock Repurchased(25.87M)(26.78M)(5.92M)0(9.04M)
Dividends Paid00000
Other Financing Activities(41.97M)(49.83M)(82.05M)(73.83M)(63.04M)
Financing Cash Flow1.78B619.27M368.75M314.77M2.54B
Effect of Forex Changes(23.28M)58.01M27.81M13.68M(63.24M)
Net Change in Cash686.91M(361.25M)(307.59M)(144.95M)302.68M
Free Cash Flow(1.04B)(890.88M)(782.92M)(135.65M)(1.2B)

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.